|
PRKD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62714286489063E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.63136171238421E-12 |
| Normal-vs-Stage2 |
1.72670000520014E-09 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
5.112300E-02 |
| Stage1-vs-Stage3 |
6.516300E-02 |
| Stage1-vs-Stage4 |
1.740380E-03 |
| Stage2-vs-Stage3 |
6.643100E-03 |
| Stage2-vs-Stage4 |
4.846800E-04 |
| Stage3-vs-Stage4 |
1.994990E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.4432899320127E-15 |
| Normal-vs-AfricanAmerican |
2.33235653013253E-12 |
| Normal-vs-Asian |
2.62778687698528E-12 |
| Caucasian-vs-AfricanAmerican |
5.830600E-01 |
| Caucasian-vs-Asian |
3.914400E-01 |
| AfricanAmerican-vs-Asian |
3.015400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.88737914186277E-15 |
| Normal-vs-Female |
2.77555756156289E-15 |
| Male-vs-Female |
7.335200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.7715611723761E-16 |
| Normal-vs-Age(41-60Yrs) |
1.63913327355658E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62470037423645E-12 |
| Normal-vs-Age(81-100Yrs) |
1.821390E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.323600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.795600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.411200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.069420E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.887200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.191200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.389200E-04 |
| Classical-VS-Follicular |
3.709200E-01 |
| Classical-VS-Other |
7.837000E-01 |
| Classical-VS-Normal |
1.64412927716739E-12 |
| Tall-VS-Follicular |
1.082430E-03 |
| Tall-VS-Other |
3.104400E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
9.582400E-01 |
| Follicular-VS-Normal |
1.69186886722628E-12 |
| Other-VS-Normal |
1.438170E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.64135371960583E-12 |
| Normal-vs-N1 |
1.62436730732907E-12 |
| N0-vs-N1 |
2.540500E-03 |
|
|
